CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives

While more than half of non-Hodgkin lymphomas (NHL) can be cured with modern frontline chemoimmunotherapy regimens, outcomes of relapsed and/or refractory (r/r) disease in subsequent lines remain poor, particularly if considered ineligible for hematopoietic stem cell transplantation. Hence, r/r NHLs...

Full description

Bibliographic Details
Main Authors: Semira Sheikh, Denis Migliorini, Noémie Lang
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/10/8/1960